Statin therapy and the risk for diabetes among adult women: Do the benefits outweigh the risk?

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 1, 2013, Pages 41-44

  Ma, Yunsheng ^a   Culver, Annie ^a   Olendzki, Barbara ^a   Merriam, Philip ^a   Lian, Bill ^a   Ockene, Ira ^a   Rossouw, Jacques ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

cardiovascular disease; diabetes; statin use; women s health

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; FEMALE; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MORTALITY; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; UNSTABLE ANGINA PECTORIS; WOMEN'S HEALTH;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; SEX DISTRIBUTION; WOMEN'S HEALTH;

EID: 84873596687     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712468499     Document Type: Review

References (27)

1. Baker W. Talati R. White C. Coleman C. (2010) Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 87: 98–107.
2. CDC (2007) Leading Causes of Death in Females. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/women/lcod/ (accessed 6 November 2012).
3. CDC (2011) National Diabetes Fact Sheet: Diagnosed and Undiagnosed Diabetes in the United States, All Ages, 2010. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
4. Cholesterol Treatment Trialists Collaborators; Mihaylova B. Emberson J. Blackwell L. Keech A. Simes J. Barnes E. et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581–590.
5. Culver A. Ockene I. Balasubramanian R. Olendzki B. Sepavich D. Wactawski-Wende J. et al. (2012) Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 172: 144–152.
6. D'Agostino R. Sr. Vasan R. Pencina M. Wolf P. Cobain M. Massaro J. et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743–753.
7. Gotto A. Jr Whitney E. Stein E. Shapiro D. Clearfield M. Weis S. et al. (2000) Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force / Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101: 477–484.
8. Gutierrez J. Ramirez G. Rundek T. Sacco R. (2012) Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 172: 909–919.
9. Katsiki N. Banach M. (2012 a) Statin use and risk of diabetes mellitus in postmenopausal women Clin Lipidol 7: 267–270.
10. Katsiki N. Banach M. (2012 b) Statins and the risk of diabetes: the debate. Arch Intern Med 172: 895–896; author reply 896–897.
11. Koh K. Quon M. Han S. Lee Y. Kim S. Shin E. (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55: 1209–1216.
12. Kostapanos M. Liamis G. Milionis H. Elisaf M. (2010) Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 8: 612–631.
13. Kostis W. Cheng J. Dobrzynski J. Cabrera J. Kostis J. (2012) Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 59: 572–582.
14. Marrugat J. Sala J. Masia R. Pavesi M. Sanz G. Valle V. et al. (1998) Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA 280: 1405–1409.
15. Mitka M. (2012) Some question use of statins to reduce cardiovascular risks in healthy women. JAMA 307: 893–894.
16. Mora S. Glynn R. Hsia J. MacFadyen J. Genest J. Ridker P. (2010) Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121: 1069–1077.
17. Mosca L. Benjamin E. Berra K. Bezanson J. Dolor R. Lloyd-Jones D. et al. (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. Circulation 123: 1243–1262.
18. Preiss D. Seshasai S. Welsh P. Murphy S. Ho J. Waters D. et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556–2564.
19. Rajpathak S. Kumbhani D. Crandall J. Barzilai N. Alderman M. Ridker P. (2009) Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32: 1924–1929.
20. Ridker P. Buring J. Rifai N. Cook N. (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297: 611–619.
21. Ridker P. Danielson E. Fonseca F. Genest J. Gotto A. Jr Kastelein J. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
22. Ridker P. MacFadyen J. Fonseca F. Genest J. Gotto A. Kastelein J. et al. (2009) Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2: 616–623.
23. Ridker P. Pradhan A. MacFadyen J. Libby P. Glynn R. (2012) Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380: 565–571.
24. Roger V. Go A. Lloyd-Jones D. Adams R. Berry J. Brown T. et al. (2011) Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 123: e18–e209.
25. Sattar N. Preiss D. Murray H. Welsh P. Buckley B. de Craen A. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735–742.
26. Taylor F. Ebrahim S. (2012) Statins work just as well in women as in men. Arch Intern Med 172: 919–920.
27. Wang K. Liu C. Chao T. Huang C. Wu C. Chen S. et al. (2012) Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 60: 1231–1238.